These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38413253)

  • 1. The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma.
    Sreedharanunni S; Singla S; Balakrishnan A; Singh A; Jamwal M; Singh N; Singh C; Jandial A; Lad D; Sharma P; Sachdeva MUS; Malhotra P; Das R
    Pathology; 2024 Jun; 56(4):556-564. PubMed ID: 38413253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
    Obr A; Procházka V; Jirkuvová A; Urbánková H; Kriegova E; Schneiderová P; Vatolíková M; Papajík T
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):762-768. PubMed ID: 30146365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
    Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
    Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.
    Short NJ; Montalban-Bravo G; Hwang H; Ning J; Franquiz MJ; Kanagal-Shamanna R; Patel KP; DiNardo CD; Ravandi F; Garcia-Manero G; Takahashi K; Konopleva M; Daver N; Issa GC; Andreeff M; Kantarjian H; Kadia TM
    Blood Adv; 2020 Nov; 4(22):5681-5689. PubMed ID: 33211826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.
    Thakurta A; Ortiz M; Blecua P; Towfic F; Corre J; Serbina NV; Flynt E; Yu Z; Yang Z; Palumbo A; Dimopoulos MA; Gutierrez NC; Goldschmidt H; Sonneveld P; Avet-Loiseau H
    Blood; 2019 Mar; 133(11):1217-1221. PubMed ID: 30692124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.
    Pollyea DA; Pratz KW; Wei AH; Pullarkat V; Jonas BA; Recher C; Babu S; Schuh AC; Dail M; Sun Y; Potluri J; Chyla B; DiNardo CD
    Clin Cancer Res; 2022 Dec; 28(24):5272-5279. PubMed ID: 36007102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.
    Martello M; Poletti A; Borsi E; Solli V; Dozza L; Barbato S; Zamagni E; Tacchetti P; Pantani L; Mancuso K; Vigliotta I; Rizzello I; Rocchi S; Armuzzi S; Testoni N; Marzocchi G; Martinelli G; Cavo M; Terragna C
    Blood Cancer J; 2022 Jan; 12(1):15. PubMed ID: 35082295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
    Forero-Castro M; Robledo C; Benito R; Bodega-Mayor I; Rapado I; Hernández-Sánchez M; Abáigar M; Maria Hernández-Sánchez J; Quijada-Álamo M; María Sánchez-Pina J; Sala-Valdés M; Araujo-Silva F; Kohlmann A; Luis Fuster J; Arefi M; de Las Heras N; Riesco S; Rodríguez JN; Hermosín L; Ribera J; Camos Guijosa M; Ramírez M; de Heredia Rubio CD; Barragán E; Martínez J; Ribera JM; Fernández-Ruiz E; Hernández-Rivas JM
    Br J Cancer; 2017 Jul; 117(2):256-265. PubMed ID: 28557976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
    Hao S; Lu X; Gong Z; Bassett RL; Hu S; Konoplev SN; Tang G; Li S; Xu J; Khanlari M; Lee HC; Manasanch EE; Weber DM; Orlowski RZ; Medeiros LJ; Lin P
    Mod Pathol; 2021 Feb; 34(2):327-335. PubMed ID: 32908255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.
    De Ramón C; Rojas EA; Cardona-Benavides IJ; Mateos MV; Corchete LA; Gutiérrez NC
    Br J Haematol; 2022 Nov; 199(3):344-354. PubMed ID: 35983648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.
    Stengel A; Kern W; Haferlach T; Meggendorfer M; Fasan A; Haferlach C
    Leukemia; 2017 Mar; 31(3):705-711. PubMed ID: 27680515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myc rearrangement redefines the stratification of high-risk multiple myeloma.
    Jin X; Li H; Zhang D; Liu S; Song Y; Zhang F; Li Z; Zhuang J
    Cancer Med; 2024 Jun; 13(11):e7194. PubMed ID: 38845529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes in Patients with Multi-Hit
    Brieghel C; Aarup K; Torp MH; Andersen MA; Yde CW; Tian X; Wiestner A; Ahn IE; Niemann CU
    Clin Cancer Res; 2021 Aug; 27(16):4531-4538. PubMed ID: 33963002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of
    Shen K; Hu DY; Chen SN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):811-818. PubMed ID: 38926972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
    Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen.
    Ou J; Xu X; Deng S; Liang H; Cai Z; Li J; Huang Z; Tang B; Wang Z; Zhou Y; Liu X; Liu Q; Zhou H
    Leuk Lymphoma; 2024 Feb; 65(2):219-227. PubMed ID: 37938093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
    Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
    Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
    Corre J; Perrot A; Caillot D; Belhadj K; Hulin C; Leleu X; Mohty M; Facon T; Buisson L; Do Souto L; Lannes R; Dufrechou S; Prade N; Orsini-Piocelle F; Voillat L; Jaccard A; Karlin L; Macro M; Brechignac S; Dib M; Sanhes L; Fontan J; Clement-Filliatre L; Marolleau JP; Minvielle S; Moreau P; Avet-Loiseau H
    Blood; 2021 Mar; 137(9):1192-1195. PubMed ID: 33080624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
    Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
    Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance.
    Baysal M; Demirci U; Umit E; Kirkizlar HO; Atli EI; Gurkan H; Gulsaran SK; Bas V; Mail C; Demir AM
    Sci Rep; 2020 Apr; 10(1):5991. PubMed ID: 32249811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.